Upstream Bio (NASDAQ:UPB – Get Free Report) is anticipated to post its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect Upstream Bio to announce earnings of ($0.7286) per share and revenue of $0.52 million for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 7:00 AM ET.
Upstream Bio (NASDAQ:UPB – Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($0.73) earnings per share for the quarter, beating the consensus estimate of ($0.74) by $0.01. Upstream Bio had a negative net margin of 4,955.67% and a negative return on equity of 48.40%. The firm had revenue of $0.77 million during the quarter, compared to analyst estimates of $0.56 million. On average, analysts expect Upstream Bio to post ($2.84) EPS for the current fiscal year and ($2.77) EPS for the next fiscal year.
Upstream Bio Price Performance
NASDAQ:UPB opened at $3.41 on Monday. The firm has a market capitalization of $186.77 million, a P/E ratio of -1.18 and a beta of 1.61. Upstream Bio has a 12-month low of $2.68 and a 12-month high of $33.68. The business has a 50 day simple moving average of $4.93 and a 200 day simple moving average of $9.51.
Analysts Set New Price Targets
UPB has been the subject of a number of recent analyst reports. Wall Street Zen lowered Upstream Bio from a “sell” rating to a “strong sell” rating in a report on Saturday, August 15th. Truist Financial cut their target price on Upstream Bio to $25.00 and set a “buy” rating on the stock in a research note on Tuesday, August 11th. JPMorgan Chase & Co. boosted their price target on Upstream Bio from $8.00 to $9.00 and gave the stock a “neutral” rating in a research report on Friday, August 14th. HC Wainwright reissued a “buy” rating and issued a $36.00 price target on shares of Upstream Bio in a research note on Wednesday, September 2nd. Finally, Weiss Ratings raised Upstream Bio from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, August 17th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Upstream Bio has a consensus rating of “Hold” and an average target price of $29.67.
View Our Latest Stock Analysis on UPB
Upstream Bio Company Profile
Upstream Bio, Inc is a clinical-stage biotechnology company focused on developing therapies for inflammatory and immune-mediated diseases. The company’s research is centered on targeting pathways involved in type 2 inflammation, which contributes to conditions affecting the respiratory system and other tissues.
Its lead product candidate is verekitug, an investigational, long-acting monoclonal antibody designed to block thymic stromal lymphopoietin (TSLP), an epithelial cytokine that plays a role in initiating and maintaining allergic and inflammatory responses.
Featured Articles
- Five stocks we like better than Upstream Bio
- Marvell Eyes a Swing for the AI Networking Fences as Markets Weigh Lumentum Price Tag
- Exxon’s Refining Profits Soared—Did Chevron Get the Same Windfall?
- Eli Lilly’s First Full Medicare Quarter: Is Volume Still Outrunning Price Cuts?
- Oracle’s AI Spending Peak Is in Sight—Can the Stock Recover?
Receive News & Ratings for Upstream Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Upstream Bio and related companies with MarketBeat.com's FREE daily email newsletter.
